Paolo Bernardi

Congenia SRL operates as pharmaceutical company, is engaged in the development of novel therapeutics for diseases associated with mitochondrial stress-induced dysfunction. The company develops small molecule drugs that target the mitochondrial permeability transition pore, a protein channel with various macromolecular components that along with mitochondrial protein p66, appears to be associated with oxidative stress-induced cell death. The company was founded in 2004 by Saverio Minucci, Pier Giuseppe Pelicci, Marco Giorgio and Paolo Bernardi and is headquartered in Milan, Italy.